



Safety Net Hospitals for Pharmaceutical Access

FOR IMMEDIATE RELEASE
Monday, June 6, 2011

Contact: Gregg Doggett
(202) 552-5859
gregg.doggett@snhpa.org

SNHPA Statement on Approval of Blood Product Manufacturers' Merger

On Wednesday, June 1, the Federal Trade Commission (FTC) [tentatively approved](#) the merger of blood product manufacturers Grifols and Talecris on the condition that the companies sell several of their assets. In a [concurring separate statement](#), however, Commissioner Julie Brill called attention to the difficulties that 340B hospitals and other providers have obtaining the blood product intravenous immunoglobulin (IVIG) at discounted prices.

Ted Slafsky, executive director of Safety Net Hospitals for Pharmaceutical Access (SNHPA), said that "although SNHPA is disappointed the merger was approved and concerned that it could further impede covered entities' already limited access to 340B-priced blood products, we applaud Commissioner Brill for recognizing the importance of discounted IVIG to our members and their vulnerable patient populations."

SNHPA has advocated for many years for improved access to IVIG at 340B prices. For more information, contact SNHPA Associate Counsel Greg Doggett at gregg.doggett@snhpa.org or (202) 552-5859.

Safety Net Hospitals for Pharmaceutical Access (SNHPA) is an association of 700 hospitals with a mission to increase the affordability and accessibility of pharmaceutical care for the nation's poor and underserved populations. For more information about SNHPA and the 340B program, visit www.snhpa.org.